• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱过度活动症症状评估工具——膀胱过度活动症症状评分

Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score.

作者信息

Homma Yukio, Yoshida Masaki, Seki Narihito, Yokoyama Osamu, Kakizaki Hidehiro, Gotoh Momokazu, Yamanishi Tomonori, Yamaguchi Osamu, Takeda Masayuki, Nishizawa Osamu

机构信息

Department of Urology, Japan Red Cross Medical Center, Tokyo, Japan.

出版信息

Urology. 2006 Aug;68(2):318-23. doi: 10.1016/j.urology.2006.02.042.

DOI:10.1016/j.urology.2006.02.042
PMID:16904444
Abstract

OBJECTIVES

Overactive bladder (OAB) is a common symptom syndrome with urgency, urinary frequency, and urgency incontinence. To collectively express OAB symptoms, we developed the overactive bladder symptom score (OABSS).

METHODS

Four symptoms--daytime frequency, nighttime frequency, urgency, and urgency incontinence--were scored. The weighing score was based on a secondary analysis of an epidemiologic database. Psychometric properties were examined in five patient groups: OAB (n = 83), asymptomatic controls (n = 34), stress incontinence (n = 29), benign prostatic hyperplasia (n = 28), and other diseases with urinary symptoms (n = 26).

RESULTS

The maximal score was defined as 2, 3, 5, and 5 for daytime frequency, nighttime frequency, urgency, and urgency incontinence, respectively. The sum score (OABSS 0 to 15) was significantly greater in the patients with OAB (8.36) than in the other patient groups (1.82 to 5.14). The distribution of the OABSS showed a clear separation between those with OAB and asymptomatic controls. The OABSS correlated positively with the individual scores (Spearman's r = 0.10 to 0.78) and quality-of-life scores assessed by the King's Health Questionnaire (Spearman's r = 0.20 to 0.49). The weighted kappa coefficients were 0.804 to 1.0 for each symptom score and 0.861 for OABSS. The posttreatment reduction in the OABSS was consistent with the global impression of patients of the therapeutic efficacy.

CONCLUSIONS

The OABSS, the sum score of four symptoms (daytime frequency, nighttime frequency, urgency, and urgency incontinence), has been developed and validated. OABSS may be a useful tool for research and clinical practice.

摘要

目的

膀胱过度活动症(OAB)是一种常见的症状综合征,表现为尿急、尿频和急迫性尿失禁。为了综合表达OAB症状,我们制定了膀胱过度活动症症状评分(OABSS)。

方法

对日间尿频、夜间尿频、尿急和急迫性尿失禁这四种症状进行评分。加权评分基于一个流行病学数据库的二次分析。在五组患者中检查了心理测量学特性:OAB患者(n = 83)、无症状对照组(n = 34)、压力性尿失禁患者(n = 29)、良性前列腺增生患者(n = 28)以及有泌尿系统症状的其他疾病患者(n = 26)。

结果

日间尿频、夜间尿频、尿急和急迫性尿失禁的最高评分分别定义为2分、3分、5分和5分。OAB患者的总分(OABSS为0至15分)(8.36分)显著高于其他患者组(1.82至5.14分)。OABSS的分布显示OAB患者与无症状对照组之间有明显区分。OABSS与各个评分呈正相关(Spearman相关系数r = 0.10至0.78),与通过国王健康问卷评估的生活质量评分也呈正相关(Spearman相关系数r = 0.20至0.49)。每个症状评分的加权kappa系数为0.804至1.0,OABSS的加权kappa系数为0.861。治疗后OABSS的降低与患者对治疗效果的总体印象一致。

结论

OABSS,即四种症状(日间尿频、夜间尿频、尿急和急迫性尿失禁)的总分,已经制定并得到验证。OABSS可能是研究和临床实践中的一个有用工具。

相似文献

1
Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score.膀胱过度活动症症状评估工具——膀胱过度活动症症状评分
Urology. 2006 Aug;68(2):318-23. doi: 10.1016/j.urology.2006.02.042.
2
Symptom severity and patient perceptions in overactive bladder: how are they related?膀胱过度活动症的症状严重程度和患者感知:它们之间有何关联?
BJU Int. 2009 Oct;104(7):968-72. doi: 10.1111/j.1464-410X.2009.08498.x. Epub 2009 Mar 10.
3
Understanding the elements of overactive bladder: questions raised by the EPIC study.了解膀胱过度活动症的要素:EPIC研究提出的问题
BJU Int. 2008 Jun;101(11):1381-7. doi: 10.1111/j.1464-410X.2008.07573.x. Epub 2008 Mar 10.
4
Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.在接受抗毒蕈碱药物治疗的膀胱过度活动症患者中,膀胱过度活动症症状评分的改善与健康相关生活质量问卷之间的相关性。
Neurourol Urodyn. 2011 Sep;30(7):1309-14. doi: 10.1002/nau.21065. Epub 2011 May 10.
5
Association between metabolic syndrome and male overactive bladder in a Japanese population based on three different sets of criteria for metabolic syndrome and the Overactive Bladder Symptom Score.基于三种不同的代谢综合征标准和膀胱过度活动症症状评分,在日本人群中,代谢综合征与男性膀胱过度活动症之间的关系。
Urology. 2012 Jun;79(6):1372-8. doi: 10.1016/j.urology.2012.03.006.
6
Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis.统计分析表明,尿急是女性膀胱过度活动症的核心症状。
J Urol. 2006 Aug;176(2):636-40. doi: 10.1016/j.juro.2006.03.062.
7
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.索利那新用于治疗伴有尿失禁的膀胱过度活动症:症状困扰及与健康相关的生活质量结果
Ann Pharmacother. 2007 Mar;41(3):391-8. doi: 10.1345/aph.1H581. Epub 2007 Mar 6.
8
Responsiveness and minimal clinically important change in overactive bladder symptom score.膀胱过度活动症症状评分的反应性和最小临床重要变化。
Urology. 2011 Oct;78(4):768-73. doi: 10.1016/j.urology.2011.06.020.
9
Reliability and validity of the Overactive Bladder Symptom Score in Spanish (OABSS-S).西班牙语版过度膀胱症状评分(OABSS-S)的信度和效度。
Neurourol Urodyn. 2012 Jun;31(5):664-8. doi: 10.1002/nau.21235. Epub 2012 Apr 4.
10
Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).四种膀胱过度活动症患者问卷的重测信度:膀胱过度活动症问卷(OAB-q)、患者膀胱状况感知问卷(PPBC)、尿急问卷(UQ)以及原发性膀胱过度活动症症状问卷(POSQ)。
Neurourol Urodyn. 2005;24(3):215-25. doi: 10.1002/nau.20110.

引用本文的文献

1
Clinical Course and Conservative Strategy for Persistent De Novo Stress Urinary Incontinence After Pelvic Organ Prolapse Repair with Transvaginal Mesh.经阴道网片修复盆腔器官脱垂后持续性新发压力性尿失禁的临床病程及保守治疗策略
Biomedicines. 2025 Aug 14;13(8):1975. doi: 10.3390/biomedicines13081975.
2
Relationship between metabolic syndrome and overactive bladder: insights from the NHANES and Mendelian randomization study.代谢综合征与膀胱过度活动症之间的关系:来自美国国家健康与营养检查调查(NHANES)及孟德尔随机化研究的见解
Diabetol Metab Syndr. 2025 Aug 22;17(1):350. doi: 10.1186/s13098-025-01883-6.
3
Mirabegron nighttime versus daytime dosing for women with overactive bladder syndrome: a randomized controlled trial.
米拉贝隆治疗女性膀胱过度活动症的夜间与日间给药对比:一项随机对照试验
Sci Rep. 2025 Aug 21;15(1):30687. doi: 10.1038/s41598-025-15780-5.
4
Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co-Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder.下尿路症状对合并膀胱过度活动症与膀胱活动低下、单纯膀胱过度活动症及单纯膀胱活动低下患者日常生活的影响。
Low Urin Tract Symptoms. 2025 Sep;17(5):e70026. doi: 10.1111/luts.70026.
5
Association and Prevalence of Lower Urinary Tract Symptoms in Individuals with Sarcopenia: A Systematic Review and Meta-Analysis.肌少症患者下尿路症状的相关性及患病率:一项系统评价和荟萃分析。
Medicina (Kaunas). 2025 Jul 3;61(7):1214. doi: 10.3390/medicina61071214.
6
Prevalence, impact on quality of life, and predictive factors of coexistence of overactive bladder and underactive bladder in men.男性膀胱过度活动症与膀胱活动低下并存的患病率、对生活质量的影响及预测因素
Sci Rep. 2025 Jul 1;15(1):21313. doi: 10.1038/s41598-025-06299-w.
7
Association Between Endogenous Equol Production and the Onset of Overactive Bladder in Postmenopausal Women.绝经后女性内源性雌马酚产生与膀胱过度活动症发病之间的关联。
J Clin Med. 2025 Jun 12;14(12):4183. doi: 10.3390/jcm14124183.
8
Association between exposure to blood heavy metal mixtures and overactive bladder risk among U.S. adults: a cross-sectional study.美国成年人血液重金属混合物暴露与膀胱过度活动症风险之间的关联:一项横断面研究。
Front Public Health. 2025 Jun 4;13:1597321. doi: 10.3389/fpubh.2025.1597321. eCollection 2025.
9
The efficacy of low-level laser therapy in alleviating genitourinary syndrome of menopause and stress urinary incontinence: the pilot study.低强度激光疗法缓解绝经后泌尿生殖综合征和压力性尿失禁的疗效:一项初步研究。
Front Med (Lausanne). 2025 May 23;12:1574646. doi: 10.3389/fmed.2025.1574646. eCollection 2025.
10
Exploratory trial of urethral submucosa injection therapy of deflux for stress urinary incontinence after radical prostatectomy.根治性前列腺切除术后压力性尿失禁的尿道黏膜下层注射德芙康治疗探索性试验。
Int J Surg Protoc. 2024 Oct 30;28(4):1-6. doi: 10.1097/SP9.0000000000000031. eCollection 2024 Oct 21.